Kruger Eliza, Giblin Shreena
Ultragenyx Pharmaceutical, Inc., Novato, California, USA.
IQVIA, London, UK.
J Health Econ Outcomes Res. 2025 May 28;12(1):201-206. doi: 10.36469/001c.137126. eCollection 2025.
Glycogen storage disease type Ia (GSDIa) is a rare, inherited metabolic disorder characterized by a deficiency in glucose 6-phosphatase. People living with GSDIa are at high risk for clinical manifestations (including hypoglycemia and hepatomegaly) and clinical complications (including hyperlipidemia, stunted growth, liver adenomas, and renal failure). Evaluating symptom management and secondary care burdens is vital to understanding the patient experience and optimizing care pathways. We sought to quantify the number of patients with GSDIa within secondary care settings across England and to evaluate the burden of disease associated with living with GSDIa. This study utilized the United Kingdom Hospital Episode Statistics (HES) database across a 69-month time period (April 2015-December 2020) to investigate National Health Service (NHS) resource use and GSDIa mortality. Patients (N = 943) with GSDIa were identified. Frequent manifestations included anemia (n = 421; 45%), hypoglycemia (n = 185; 20%), and hepatomegaly (n = 152; 16%). On average, patients had a total of 8 events/year, including 2 elective events, 2 nonelective emergencies, 1 outpatient visit, and 3 daycase visits. In the entire HES population, there was approximately 1 (~60% elective, ~40% nonelective) event/year. The highest total number of events across the entire patient journey tracked within the HES occurred with adolescents (12-17 years) who had an average of 28.5 events. Average length of stay was greatest in the pediatric infantile (0-2 years) population with 4.6 days and 3.4 days for nonelective and elective events, respectively. When benchmarked against the general population, patients with GSDIa had a mortality rate of 4.3%, compared with 0.9% for the entire HES population. The average age at mortality was 14.3 years lower for patients with GSDIa vs the entire HES population (63.7 years vs 78.0 years). This study demonstrates high burden associated with GSDIa. Complications are a key driver of NHS resource use. Mortality associated with GSDIa in hospitalized patients is higher than the general population. GSDIa imposes a large burden on the healthcare system. There is a clear unmet need for patients with GSDIa, and complications are a substantial driver of resource use and burden of disease.
Ia型糖原贮积病(GSDIa)是一种罕见的遗传性代谢紊乱疾病,其特征是葡萄糖6磷酸酶缺乏。患有GSDIa的人出现临床表现(包括低血糖和肝肿大)和临床并发症(包括高脂血症、生长发育迟缓、肝腺瘤和肾衰竭)的风险很高。评估症状管理和二级护理负担对于了解患者体验和优化护理途径至关重要。我们试图量化英格兰二级护理机构中GSDIa患者的数量,并评估与GSDIa相关的疾病负担。本研究利用英国医院事件统计(HES)数据库,在69个月的时间段(2015年4月至2020年12月)内调查国民健康服务(NHS)资源使用情况和GSDIa死亡率。确定了943例GSDIa患者。常见表现包括贫血(n = 421;45%)、低血糖(n = 185;20%)和肝肿大(n = 152;16%)。患者平均每年共有8次事件,包括2次择期事件、2次非择期急诊、1次门诊就诊和3次日间手术就诊。在整个HES人群中,每年约有1次事件(约60%为择期事件,约40%为非择期事件)。在HES跟踪的整个患者病程中,事件总数最高的是青少年(12 - 17岁),平均有28.5次事件。住院时间平均最长的是小儿婴儿期(0 - 2岁)人群,非择期事件为4.6天,择期事件为3.4天。与普通人群相比,GSDIa患者的死亡率为4.3%,而整个HES人群的死亡率为0.9%。GSDIa患者的平均死亡年龄比整个HES人群低14.3岁(63.7岁对78.0岁)。这项研究表明GSDIa相关负担很重。并发症是NHS资源使用的关键驱动因素。住院患者中与GSDIa相关的死亡率高于普通人群。GSDIa给医疗系统带来了巨大负担。GSDIa患者存在明显未满足的需求,并发症是资源使用和疾病负担的重要驱动因素。